eligibility_summary
Eligibility: Adults ≥18, fluent English, able to walk unaided ≥6 min (20–30 min moderate exercise), starting first-time checkpoint inhibitor monotherapy (avelumab, cemiplimab, ipilimumab, nivolumab, or pembrolizumab) for adjuvant melanoma or neoadjuvant melanoma, cuSCC, or Merkel cell carcinoma, willing to follow protocol, consent/HIPAA. Exclude: contraindicating CV/post-op issues, active TB/HBV/HCV/HIV/COVID-19, pregnancy, or other risks per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests a same-day exercise intervention to enhance responses to standard checkpoint inhibitors in cutaneous melanoma, cuSCC, and Merkel cell carcinoma. Interventions: • Exercise: supervised 30 min moderate cycling immediately before each infusion (non-drug behavioral/physiologic intervention). Mechanism: acute exercise mobilizes and traffics effector immune cells (NK cells, CD8+ T cells), boosts catecholamine/IL‑6 signaling, improves perfusion, and may reduce immunosuppressive milieu. • Checkpoint inhibitors (monoclonal antibodies): anti–PD‑1 (nivolumab, pembrolizumab, cemiplimab), anti–PD‑L1 (avelumab), anti–CTLA‑4 (ipilimumab). Mechanism: block PD‑1/PD‑L1 or CTLA‑4 to release T‑cell inhibition, enhancing priming and effector function. Targets: PD‑1/PD‑L1 and CTLA‑4 pathways on T cells, NK and CD8+ T cells, adrenergic/IL‑6 signaling, tumor microenvironment perfusion.